

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Certolizumab pegol for treating moderate to severe plaque psoriasis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

Yes.

As in previous technology appraisals on psoriasis, the committee has included a recommendation that when using the Psoriasis Area and Severity Index (PASI) scale, healthcare professionals should take into account skin colour and how this could affect the PASI score, and make any adjustments they consider appropriate. It also included a recommendation that when using the Dermatology Life Quality Index (DLQI), healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties, which could affect a person's responses to the DLQI, and make any adjustments they consider appropriate.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

Yes.

Statements from patient and professional groups noted that certolizumab pegol is a safe option for anyone who wants to become pregnant and during

pregnancy. The committee considered the potential benefits of certolizumab pegol in this patient population.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The committee's considerations on pregnancy and breastfeeding are described in sections 3.11 and 3.24 of the ACD. Recommendations on the

interpretation of the PASI and DLQI scales are described in section 3.25 of the ACD.

Approved by Associate Director (name): ...Melinda Goodall.....

Date: 16/11/2018

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

N/A – recommendations unchanged

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

N/A– recommendations unchanged

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified

in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A – recommendations unchanged

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The committee's considerations on pregnancy and breastfeeding are described in section 3.25 of the FAD. Recommendations on the interpretation of the PASI and DLQI scales are described in section 3.26 of the FAD.

Approved by Associate Director (name): Jasdeep Hayre

Date: 22/02/2019

